Articles from Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver Leave Benefit as an additional family-friendly offering for employees of the company and its affiliates. The new global benefit includes a minimum of ten days of financially protected leave.1 This initiative builds on the recent rollout of the global Fertility Benefit at Merck KGaA, Darmstadt, Germany and its affiliates, and advances the company’s journey to provide an inclusive suite of benefits that support employees’ holistic well-being.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, awarded Professor Lauren Gardner, representing Johns Hopkins University, Baltimore, USA, with the Future Insight Prize 2024 worth 500.000 € for her contributions to develop advanced Artificial Intelligence (AI) systems to help quickly discover and control future pandemics.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types. NMS-293 is in early clinical development for the treatment of patients with BRCA-mutated tumors as a single agent and in combination with temozolomide in recurrent glioblastoma.

The email addresses in the contacts section of the release dated November 22, 2021 03:00 AM Eastern Standard Time have been updated to: gangolf.schrimpf@emdgroup.com and investor.relations@emdgroup.com

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call.